Author

S. Bahnassy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

R. B. Riggins· 3 shared H. Stires· 2 shared A. M. Rozeboom· 1 shared A. O. Olukoya· 1 shared B. G. Bitler· 1 shared B. M. Jacobsen· 1 shared B. R. Corr· 1 shared C. Benitez· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. B. Riggins

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer

S. Bahnassy, H. Stires, L. Jin, S. Tam, D. Mobin, M. Balachandran, M. B. Podar, M. D. McCoy, R. A. Beckman, R. B. Riggins

The paper develops two in vitro models of endocrine therapy-resistant HER2+/ER+ breast cancer and identifies lipid metabolism and ferroptosis as therapeutic vulnerabilities.

bioRxiv · Aug 21, 2023Cancer Biology

WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in breast and gynecologic cancers

J. L. Sottnik, M. T. Shackleford, F. R. Villagomez, S. Bahnassy, S. Oesterreich, J. Hu, Z. Madak-Erdogan, R. B. Riggins, B. R. Corr, L. S. Cook, L. S. Trevino, B. G. Bitler, M. J. Sikora

This study identifies WNT4's role in regulating cancer metabolism through mitochondrial intracellular signaling in breast and gynecologic cancers, linking genetic variants to metabolic remodeling.

bioRxiv · Jul 15, 2022Cancer Biology

Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer

A. O. Olukoya, H. Stires, S. Bahnassy, S. Persaud, Y. Guerra, S. Ranjit, S. Ma, M. I. Cruz, C. Benitez, A. M. Rozeboom, H. Ceuleers, D. L. Berry, B. M. Jacobsen, G. V. Raj, R. B. Riggins

This study shows Riluzole reduces growth and improves response to endocrine therapy in ER+ breast cancer models.

bioRxiv · Jul 30, 2020 · PreprintCancer Biology